Supplementary figures 1-15 from A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers

MLA

Markus D. Siegelin, et al. Supplementary Figures 1-15 from A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers. Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....002a4e15a2bd6b46719276556fefbdfb&authtype=sso&custid=ns315887.

APA

Markus D. Siegelin, James M. Angelastro, Lloyd A. Greene, Peter Canoll, Jeffrey N. Bruce, Takashi Tsujiuchi, Lily Chau, Chang Shu, Basil A. Horst, & Georg Karpel-Massler. (2023). Supplementary figures 1-15 from A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.

Chicago

Markus D. Siegelin, James M. Angelastro, Lloyd A. Greene, Peter Canoll, Jeffrey N. Bruce, Takashi Tsujiuchi, Lily Chau, Chang Shu, Basil A. Horst, and Georg Karpel-Massler. 2023. “Supplementary Figures 1-15 from A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers,” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....002a4e15a2bd6b46719276556fefbdfb&authtype=sso&custid=ns315887.